Anxiolytic effects of prelimbic 5-HT1A receptor activation in the hemiparkinsonian rat

Behavioural Brain Research

Volumn 277, Issue , 2015, Pages 211-220

  Hui, Yan Ping ^a   Wang, Tao ^a   Han, Ling Na ^a   Li, Li Bo ^a   Sun, Yi Na ^a   Liu, Jian ^a   Qiao, Hong Fei ^a   Zhang, Qiao Jun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

5 HT1A receptor; 6 Hydroxydopamine; Anxiety; Parkinson's disease; Prelimbic medial prefrontal cortex; Rat

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 3; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OXIDOPAMINE; SEROTONIN 1A RECEPTOR; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANXIOLYTIC AGENT; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN DAMAGE; CELL COUNT; CELL DENSITY; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; ELEVATED PLUS MAZE TEST; IMMUNOCOMPETENT CELL; LIMBIC SYSTEM; MALE; MEDIAL FOREBRAIN BUNDLE; NERVE CELL; NONHUMAN; OPEN FIELD TEST; PARKINSONISM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; REGULATORY MECHANISM; SHAM PROCEDURE; VENTROMEDIAL PREFRONTAL CORTEX; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PARKINSON DISEASE; SPRAGUE DAWLEY RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DISEASE MODELS, ANIMAL; MALE; NEURONS; PARKINSON DISEASE; PIPERAZINES; PYRIDINES; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 84912103923     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.04.053     Document Type: Article

References (81)

1. Vertes R.P. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 2004, 51(1):32-58.
2. Morgan M.A., LeDoux J.E. Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear in rats. Behav Neurosci 1995, 109(4):681-688.
3. Duncan G.E., Knapp D.J., Breese G.R. Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res 1996, 713(1/2):79-91.
4. Jinks A.L., McGregor I.S. Modulation of anxiety-related behaviours following lesions of the prelimbic or infralimbic cortex in the rat. Brain Res 1997, 772(1/2):181-190.
5. Broersen L.M., Abbate F., Feenstra M.G., de Bruin J.P., Heinsbroek R.P., Olivier B. Prefrontal dopamine is directly involved in the anxiogenic interoceptive cue of pentylenetetrazol but not in the interoceptive cue of chlordiazepoxide in the rat. Psychopharmacology (Berl) 2000, 149(4):366-376.
6. Gonzalez L.E., Rujano M., Tucci S., Paredes D., Silva E., Alba G., et al. Medial prefrontal transection enhances social interaction. I: Behavioral studies. Brain Res 2000, 887(1):7-15.
7. Lacroix L., Spinelli S., Heidbreder C.A., Feldon J. Differential role of the medial and lateral prefrontal cortices in fear and anxiety. Behav Neurosci 2000, 114(6):1119-1130.
8. Sullivan R.M., Gratton A. Behavioral effects of excitotoxic lesions of ventral medial prefrontal cortex in the rat are hemisphere-dependent. Brain Res 2002, 927(1):69-79.
9. Shah A.A., Treit D. Infusions of midazolam into the medial prefrontal cortex produce anxiolytic effects in the elevated plus-maze and shock-probe burying tests. Brain Res 2004, 996(1):31-40.
10. Resstel L.B., Joca S.R., Guimaraes F.G., Correa F.M. Involvement of medial prefrontal cortex neurons in behavioral and cardiovascular responses to contextual fear conditioning. Neuroscience 2006, 143(2):377-385.
11. Resstel L.B., Souza R.F., Guimaraes F.S. Anxiolytic-like effects induced by medial prefrontal cortex inhibition in rats submitted to the Vogel conflict test. Physiol Behav 2008, 93(1/2):200-205.
12. Solati J., Salari A.A., Bakhtiari A. 5-HT(1A) and 5-HT(1B) receptors of medial prefrontal cortex modulate anxiogenic-like behaviors in rats. Neurosci Lett 2011, 504(3):325-329.
13. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38(8):1083-1152.
14. 1A selective agonists. Eur J Pharmacol 1986, 128(3):295-298.
15. Araneda R., Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991, 40(2):399-412.
16. Feighner J.P., Boyer W.F. Serotonin-1A anxiolytics: an overview. Psychopathology 1989, 22(Suppl. 1):21-26.
17. Akimova E., Lanzenberger R., Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009, 66(7):627-635.
18. 1A receptors in the treatment of Schizophrenia and Parkinson's disease. CNS Neurosci Ther 2011, 17(1):58-65.
19. Inoue T., Koyama T., Yamashita I. Effect of conditioned fear stress on serotonin metabolism in the rat brain. Pharmacol Biochem Behav 1993, 44(2):371-374.
20. Yoshioka M., Matsumoto M., Togashi H., Saito H. Effects of conditioned fear stress on 5-HT release in the rat prefrontal cortex. Pharmacol Biochem Behav 1995, 51(2/3):515-519.
21. McKinlay A., Grace R.C., Dalrymple-Alford J.C., Anderson T., Fink J., Roger D. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Rel Disord 2008, 14(1):37-42.
22. Jungnickel J., Kalve I., Reimers L., Nobre A., Wesemann M., Ratzka A., et al. Topology of intrastriatal dopaminergic grafts determines functional and emotional outcome in neurotoxin-lesioned rats. Behav Brain Res 2011, 216:129-135.
23. Kuan W.L., Zhao J.W., Barker R.A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl) 2008, 197(2):279-293.
24. Delaville C., Chetrit J., Abdallah K., Morin S., Cardoit L., De Deurwaerdere P., et al. Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism. Neurobiol Dis 2012, 45(2):763-773.
25. Carvalho M.M., Campos F.L., Coimbra B., Pego J.M., Rodrigues C., Lima R., et al. Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. Mol Neurodegener 2013, 8:14.
26. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., et al. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 2008, 86(9):2050-2061.
27. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156(4):830-840.
28. Scholtissen B., Verhey F.R., Steinbusch H.W., Leentjens A.F. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J Neural Transm 2006, 113(1):59-73.
29. Huot P., Fox S.H., Brotchie J.M. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011, 95:163-212.
30. 1A receptor stimulation in a rat model of Parkinson's disease. Neuroscience 2009, 162(4):1091-1100.
31. 3 receptors in 6-hydroxydopamine-induced parkinsonian rats. Neuroscience 2010, 169(3):1315-1325.
32. 1A receptor agonist and expression of the receptor in parvalbumin-positive neurons in the rat. Neurochem Int 2011, 59(5):618-627.
33. 2A/2C receptor stimulation in the rat. Brain Res 2010, 1312:127-137.
34. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, New York. 4th ed.
35. 1A receptor stimulation in the rat. Neuroscience 2009, 159(2):850-861.
36. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 1988, 31:959-962.
37. Rodgers R.J., Dalvi A., Anxiety defence and the elevated plus-maze. Neurosci Biobehav Rev 1997, 21(6):801-810.
38. Sato H., Skelin I., Diksic M. Acute desipramine treatment reduces regional serotonin synthesis rates, while chronic treatment elevates rates, in a rat model of depression: an autoradiographic study. Neurochem Int 2011, 58:759-766.
39. Higashino K., Ago Y., Umehara M., Kita Y., Fujita K., Takuma K., et al. Effects of acute and chronic administration of venlafaxine and desipramine on extracellular monoamine levels in the mouse prefrontal cortex and striatum. Eur J Pharmacol 2014, 729:86-93.
40. Muller C.P., Pum M.E., Amato D., Schüttler J., Huston J.P., Silva M.A. The in vivo neurochemistry of the brain during general anesthesia. J Neurochem 2011, 119(3):419-446.
41. Eskow Jaunarajs K.L., Dupre K.B., Ostock C.Y., Button T., Deak T., Bishop C. Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol 2010, 21(7):627-637.
42. Zhang X.Q., Egeland M., Svenningsson P. Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology (Berl) 2011, 218(4):621-634.
43. 1A receptors in the dorsal hippocampus mediate the anxiogenic effect induced by the stimulation of 5-HT neurons in the median raphe nucleus. Eur Neuropsychopharmacol 2008, 18(4):286-294.
44. 2C receptors in the amygdala of mice. Neuropharmacology 2012, 62:474-484.
45. Sousa N., Almeida O.F., Wotjak C.T. A Hitchhiker's guide to behavioral analysis in laboratory rodents. Genes Brain Behav 2006, 5(Suppl. 2):5-24.
46. Fink J.S., Smith G.P. Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats. Brain Res 1980, 199:359-384.
47. Jones G.H., Robbins T.W. Differential-effects of mesocortical, mesolimbic, and mesostriatal dopamine depletion on spontaneous, conditioned, and drug-induced locomotor-activity. Pharmacol Biochem Behav 1992, 43:887-895.
48. Steinbusch H.W. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 1981, 6(4):557-618.
49. Van Bockstaele E.J., Biswas A., Pickel V.M. Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. Brain Res 1993, 624(1/2):188-198.
50. 1A receptor in the rat brain: correlation with receptor binding. J Neurosci 1992, 12(2):440-453.
51. Santana N., Bortolozzi A., Serrats J., Mengod G., Artigas F. Expression of serotonin-1A and serotonin-2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2004, 14(10):1100-1109.
52. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berl) 1995, 121(1):1-26.
53. Kostowski W., Plaznik A., Stefanski R. Intra-hippocampal buspirone in animal models of anxiety. Eur J Pharmacol 1989, 168(3):393-396.
54. 1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur J Pharmacol 1993, 249(3):341-351.
55. 1A receptors in the dorsal hippocampus mediate the anxiogenic effect induced by the stimulation of 5-HT neurons in the median raphe nucleus. Eur Neuropsychopharmacol 2008, 18(4):286-294.
56. 1A receptors in the rat basolateral amygdala induces both anxiolytic and antipanic-like effects. Behav Brain Res 2013, 246:103-110.
57. Shimizu H., Tatsuno T., Tanaka H., Hirose A., Araki Y., Nakamura M. Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J Pharmacol 1992, 59(1):105-112.
58. 1A receptors is responsible for the anticonflict effect of ipsapirone in rats. J Pharm Pharmacol 1992, 44(9):780-782.
59. Bystritsky A., Pontillo D., Powers M., Sabb F.W., Craske M.G., Bookheimer S.Y. Functional MRI changes during panic anticipation and imagery exposure. Neuroreport 2001, 12(18):3953-3957.
60. Dilger S., Straube T., Mentzel H.J., Fitzek C., Reichenbach J.R., Hecht H., et al. Brain activation to phobia-related pictures in spider phobic humans: an event-related functional magnetic resonance imaging study. Neurosci Lett 2003, 348(1):29-32.
61. Neumeister A., Bain E., Nugent A.C., Carson R.E., Bonne O., Luckenbaugh D.A., et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004, 24(3):589-591.
62. Singewald N., Salchner P., Sharp T. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 2003, 53(4):275-283.
63. 2A/2C receptors in the firing activity of pyramidal neurons of medial prefrontal cortex in a rodent model of Parkinson's disease. Exp Neurol 2009, 219(1):239-248.
64. 7 receptor agonist on pyramidal neurons in medial frontal cortex of normal and 6-hydroxydopamine-lesioned rats: an electrophysiological study. Neuroscience 2011, 190:328-338.
65. Sesack S.R., Deutch A.Y., Roth R.H., Bunney B.S. Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol 1989, 290(2):213-242.
66. McDonald A.J., Mascagni F., Guo L. Projections of the medial and lateral prefrontal cortices to the amygdala: a Phaseolus vulgaris leucoagglutinin study in the rat. Neuroscience 1996, 71(1):55-75.
67. Hajos M., Richards C.D., Szekely A.D., Sharp T. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience 1998, 87(1):95-108.
68. Peyron C., Petit J.M., Rampon C., Jouvet M., Luppi P.H. Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 1998, 82(2):443-468.
69. Likhtik E., Pelletier J.G., Paz R., Pare D. Prefrontal control of the amygdala. J Neurosci 2005, 25(32):7429-7437.
70. 1A receptors control 5-HT release in the rat medial prefrontal cortex. Neuroreport 1999, 10(7):1441-1445.
71. 1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 1999, 126(8):1741-1750.
72. Celada P., Puig M.V., Casanovas J.M., Guillazo G., Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 2011, 21(24):9917-9929.
73. Kaya A.H., Vlamings R., Tan S., Lim L.W., Magill P.J., Steinbusch H.W., et al. Increased electrical and metabolic activity in the dorsal raphe nucleus of parkinsonian rats. Brain Res 2008, 1221:93-97.
74. Iversen S.D. 5-HT and anxiety. Neuropharmacology 1984, 23(12B):1553-1560.
75. Briley M., Chopin P., Moret C. Effect of serotonergic lesion on "anxious" behaviour measured in the elevated plus-maze test in the rat. Psychopharmacology (Berl) 1990, 101(2):187-189.
76. Rosenkranz J.A., Grace A.A. Cellular mechanisms of infralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. J Neurosci 2002, 22(1):324-337.
77. Quirk G.J., Likhtik E., Pelletier J.G., Pare D. Stimulation of medial prefrontal cortex decreases the responsiveness of central amygdala output neurons. J Neurosci 2003, 23(25):8800-8807.
78. 4 receptor agonist. Psychopharmacology (Berl) 2006, 188:244-251.
79. 4 receptors in GABAergic neurons of the primate brain. Nature 1996, 381:245-248.
80. 4 receptors in the rat brain - immunocytochemical study. J Physiol Pharmacol 2000, 51:205-221.
81. 2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced parkinsonian rats. Brain Res 2005, 1045:229-233.